Synmosa Biopharma Corporation (TPEX:4114)
Taiwan · Delayed Price · Currency is TWD 27.85
0.00 (0.00%)
Nov 10, 2026, 1:30 PM CST
Synmosa Biopharma Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15,070 | 16,248 | 14,499 | 14,706 | 16,021 | 7,016 | |
Market Cap Growth | -8.93% | 12.06% | -1.41% | -8.21% | 128.36% | 2.96% |
Enterprise Value | 16,839 | 18,148 | 16,554 | 17,100 | 19,459 | 10,892 |
Last Close Price | 27.85 | 29.24 | 27.69 | 27.78 | 31.36 | 13.58 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 18.23 | 19.77 | 21.18 | 24.72 | 20.05 | 23.09 |
Forward PE | - | 15.36 | 15.63 | 18.08 | 21.79 | 51.28 |
PS Ratio | 2.26 | 2.63 | 2.61 | 2.86 | 3.65 | 2.17 |
PB Ratio | 1.53 | 1.61 | 1.73 | 1.82 | 2.41 | 1.15 |
P/TBV Ratio | 1.88 | 1.95 | 2.16 | 2.39 | 3.38 | 1.67 |
P/FCF Ratio | 76.25 | 104.06 | 25.61 | 48.24 | 31.98 | 19.39 |
P/OCF Ratio | 39.24 | 39.48 | 18.57 | 28.73 | 25.42 | 15.42 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.52 | 2.93 | 2.98 | 3.33 | 4.44 | 3.37 |
EV/EBITDA Ratio | 16.32 | 16.70 | 15.75 | 18.43 | 25.58 | 22.83 |
EV/EBIT Ratio | 24.64 | 23.31 | 22.34 | 27.72 | 42.24 | 58.33 |
EV/FCF Ratio | 85.20 | 116.23 | 29.24 | 56.09 | 38.84 | 30.10 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.34 | 0.25 | 0.30 | 0.30 | 0.51 | 0.57 |
Debt / EBITDA Ratio | 3.13 | 2.26 | 2.37 | 2.56 | 4.32 | 7.15 |
Debt / FCF Ratio | 16.86 | 16.10 | 4.50 | 7.98 | 6.70 | 9.57 |
Net Debt / Equity Ratio | 0.06 | -0.04 | 0.08 | 0.10 | 0.29 | 0.41 |
Net Debt / EBITDA Ratio | 0.53 | -0.38 | 0.63 | 0.84 | 2.55 | 5.19 |
Net Debt / FCF Ratio | 2.79 | -2.68 | 1.18 | 2.57 | 3.87 | 6.84 |
Asset Turnover | 0.46 | 0.47 | 0.46 | 0.45 | 0.41 | 0.31 |
Inventory Turnover | 1.73 | 1.74 | 1.83 | 1.99 | 1.97 | 1.59 |
Quick Ratio | 1.30 | 1.93 | 1.54 | 1.35 | 1.10 | 0.95 |
Current Ratio | 2.03 | 2.95 | 2.42 | 2.14 | 1.73 | 1.64 |
Return on Equity (ROE) | 5.91% | 6.69% | 5.68% | 5.49% | 9.71% | 1.93% |
Return on Assets (ROA) | 3.05% | 3.70% | 3.85% | 3.36% | 2.68% | 1.13% |
Return on Invested Capital (ROIC) | 5.25% | 6.42% | 5.87% | 4.76% | 4.58% | 1.61% |
Return on Capital Employed (ROCE) | 6.10% | 6.60% | 7.20% | 6.40% | 5.20% | 2.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.49% | 5.06% | 4.72% | 4.04% | 4.99% | 4.33% |
FCF Yield | 1.31% | 0.96% | 3.91% | 2.07% | 3.13% | 5.16% |
Dividend Yield | 2.83% | 2.63% | 1.91% | 1.56% | 1.22% | 2.15% |
Payout Ratio | 32.96% | 33.17% | 33.41% | 32.69% | 18.60% | 26.32% |
Buyback Yield / Dilution | -5.16% | -7.00% | -3.49% | -3.84% | 0.79% | -2.35% |
Total Shareholder Return | -2.34% | -4.37% | -1.57% | -2.28% | 2.01% | -0.21% |